M&A Deal Summary

Medexus Pharma Acquires IXINITY

On February 28, 2020, Medexus Pharma acquired life science company IXINITY from Aptevo Therapeutics for 30M USD

Acquisition Highlights
  • This is Medexus Pharma’s 3rd transaction in the Life Science sector.
  • This is Medexus Pharma’s 2nd largest (disclosed) transaction.
  • This is Medexus Pharma’s 2nd transaction in the United States.
  • This is Medexus Pharma’s 2nd transaction in Illinois.

M&A Deal Summary
Date 2020-02-28
Target IXINITY
Sector Life Science
Buyer(s) Medexus Pharma
Sellers(s) Aptevo Therapeutics
Deal Type Divestiture
Deal Value 30M USD

Target

IXINITY

Chicago, Illinois, United States
IXINITY is a medicine used to replace clotting factor (factor IX) that is missing in adults and children at least 12 years of age with hemophilia B. Hemophilia B is also called congenital factor IX deficiency. Hemophilia B is an inherited bleeding disorder that prevents clotting.

Search 201,157 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Medexus Pharma

Toronto, Ontario, Canada
Category Company
Sector Life Science
Employees98
Revenue 108M USD (2023)
DESCRIPTION

Medexus Pharma is a pharmaceutical company dedicated to serving the needs of the pediatric community. Pediapharm’s product portfolio includes NYDA®, a breakthrough treatment for head lice; Relaxa™, an osmotic laxative used to treat constipation; EpiCeram®, a non-steroid emulsion for eczema; naproxen suspension, indicated to treat pain and inflammation due to various conditions, including Juvenile Idiopathic Arthritis; Rupall™, an innovative new allergy medication with a unique mode of action; Otixal™, the first and only antibiotic and steroid combination ear drop available in single, sterile, preservative-free and unit-dose packaging; and Cuvposa™, for chronic severe drooling, a condition affecting a significant proportion of cerebral palsy patients. Medexus Pharmaceuticals is headquartered in Toronto, Canada.

DEAL STATS #
Overall 3 of 3
Sector (Life Science) 3 of 3
Type (Divestiture) 2 of 2
State (Illinois) 2 of 2
Country (United States) 2 of 2
Year (2020) 1 of 1
Size (of disclosed) 2 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2018-10-16 Medac Pharma

Chicago, Illinois, United States

Medac Pharma, Inc. is a pharmaceutical company. Medac Pharma focused on the development and commercialization of treatments for autoimmune diseases and oncology. Medac Pharma, Inc. was founded in 2012 and is headquartered in Chicago, Illinois.

Buy $50M

Seller(S) 1

SELLER

Aptevo Therapeutics

Seattle, Washington, United States
Category Company
Founded 2016
Sector Life Science
DESCRIPTION

Aptevo Therapeutics is a biotech company primarily focused on bringing novel oncology and hematology therapeutics to market. Company leverage the innovative ADAPTIR platform technology, a unique approach to cancer immunotherapy, to improve outcomes for cancer patients. Based in Seattle, Washington, the company is proud of its empowering work environment, entrepreneurial culture, and proprietary platform technology. As a result, Aptevo has been able to attract some of the most innovative minds in the field. Many of our team members have notable experience with other pioneering biotech companies including Trubion, ZymoGenetics, Immunex, Dendreon, and VLST.

DEAL STATS #
Overall 2 of 2
Sector (Life Science) 1 of 1
Type (Divestiture) 2 of 2
State (Illinois) 1 of 1
Country (United States) 2 of 2
Year (2020) 1 of 1
Size (of disclosed) 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2017-08-31 Aptevo Therapeutics - Hyperimmune Commercial Products

Seattle, Washington, United States

Aptevo Therapeutics, Inc. - Hyperimmune Commercial Products comprises WinRho SDF, HepaGam B, and VARIZIG. WinRho SDF for autoimmune platelet disorder and hemolytic disease of the newborn; HepaGam B for the prevention of Hepatitis B following liver transplantation and for treatment following hepatitis B exposure; and VARIZIG for treatment following exposure to varicella zoster virus for individuals with compromised immune systems.

Sell $75M
Mergr

Product

Company

Legal